Maxvax Biotechnology Secures RMB 200 Million in Convertible Bonds Financing
Immunotherapy biotech company Maxvax Biotechnology, based in Chengdu, has announced the successful closure of a...
Company
Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...
HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has reached an agreement to divest its...
Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China
US-based medical device leader Boston Scientific Corporation (NYSE: BSX) has announced the market launch of...
Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US...
Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...
BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074
Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...
Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...
Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation
Shenzhen-based QuantumPharm Inc., operating under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...
Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006
China-based Jiangxi Jemincare Group has announced that it has received clinical trial approval from the...
CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT)...
We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange
China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital...
Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion
China’s Shinva Medical Instrument Co., Ltd (SHA: 600587) has announced its intention to acquire a...
Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial...
CanSino Biologics’ Menhycia Receives Market Approval in Indonesia
China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan...
CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
MicuRx Pharmaceuticals’ MRX-5 Receives FDA Orphan Drug Designation for NTM Infections
Sino-US firm MicuRx Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA)...
Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...
CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...